Ghasemzadeh A
ORCID: 0000-0003-4286-3552
· 7 papers in corpus
observational
2026
Introduction Approximately 1-5% of pregnant women experience recurrent pregnancy loss (RPL). Early detection and evaluation of high-risk variables allow for the initiation of recommended treatments while also reducing the likelihood of RPL …
rct
2025
OBJECTIVE: For successful embryo implantation in women with high pulsatility, uterine vascular resistance and pulsatility must be reduced. We examined the effects of amlodipine on uterine pulsatility index (PI), resistance index (RI), and e…
rct
2025
BACKGROUND: Background: Infertility is a global public health concern, and controlled ovarian stimulation (COS) plays a crucial role in assisted reproductive technologies (ART) by facilitating the retrieval of multiple oocytes. This single-…
other
2025
Despite advancements in assisted reproductive technology (ART), recurrent implantation failure (RIF) continues to pose a significant challenge to achieving pregnancy. We included 2,463 retrospective RIF patients with no gynecological and an…
nonrandomized-trial
2023
BACKGROUND: Endometriosis is a chronic inflammatory disease affecting about 10% of women of reproductive age. Endometrioma is the most common presentation of endometriosis in ovaries. OBJECTIVES: Herein, the authors study the effect of the…
nonrandomized-trial
2022
BACKGROUND: Growth hormone (GH) is a potential treatment in the assisted reproductive technology (ART) to improve endometrial receptivity and thickness. In the current study, we investigated the effect of the intrauterine administration of …
rct
2019
BACKGROUND: Oral progesterone is recommended as an alternative to gonadotropin-releasing hormone (GnRH) agonists and antagonists to prevent luteinizing hormone (LH) surge in assisted reproductive technology (ART) cycles. However, there are …